Topic: The Use of Biomarkers-A Chemo Sensitivity Report For Cholangiocarcinom
As the use of biomarkers will be the vision of ASCO for researching and treating cancers in the next 10 years. I took the liberty to send the biopsy tissues I had from my 2nd liver resection to the lab.And 2 weeks later, I got my report back and I would like to share with you.
The Lab. is Caris Life Sciences.(800-901-5177) in Phoenix,Arizona.
The test report is a"Target Now summary" with about 10 other pages of info. about biomarkers that they had done for me.
The requirement to get this done is either the request from your oncologist or surgeon.
The cost is depends on your insurance.
Is it worth to have one done? Depends on what your expectation from the report.
Here is how the report looks like.( I have a hard time to copy the scan document and paste here,so I just type it out here.)
Caris Target Now Final Report
Clinical Dx=cholangiocarcinoma based on pathology report;Liver right lobe,wedge biopsy.(3cm)
Agents Associated with Agents Associated with* LACK OF*
Clinical Benefit Clinical Benefit
**On NCCN compendium**
**OFF NCCN compendium**
The biomarkers they tested are ERCC1,TOP2A,TOP2B,TS,PTEN , EGFR,BRAF,KRAS,RRM2,VDR,VEGFR2,BRCA2 ,TOPO1,Her2/Neu, MGMT and PTGS2,c-kit,RRM1 and a microarray analysis of about 60 RNA expressions of the tissue sample(included some of the above biomarkers) This RNA expression analysis just indicated whether my sample is UNDEREXPRESSED , NO CHANGE OR OVEREXPRESSED on each of the RNA they tested.
The methods they used in the tests included IHC, FISH, Molecular and Microarrayillumina.
The Lab also provided a brief description on the biomarkers they tested;and the references for the agents that show sensitivity to my tumor sample as well as the ones that show lack of the clinical benefits.
I will try to digest the report and report to all of you what I think about this test.
But I have already one complaint.
The "Caris Target Now report" does not give ranking(ie: high to low sensitivity) of the chemo or molecularly targeted agents that I should use first .Instead they recommended the decision should be made by the oncologists.
That means one thing I have to be hurry to read up on the biomarkers they tested and try to find the most sensitive agents to use first when I talk with my oncologist.